Biology Reference
In-Depth Information
Hanasato N, Oka M, Muramatsu M, Nishino M, Adachi H, Fukuchi Y (1999) E-4010, a selective
phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats. Am J
Physiol 277:L225-L232
Hanson KA, Ziegler JW, Rybalkin SD, Miller JW, Abman SH, Clarke WR (1998) Chronic
pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Am J Physiol
275:L931-L941
Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, Jones PL,
Maitland ML, Michelakis ED, Morrell NW, Newman JH, Rabinovitch M, Schermuly R,
Stenmark KR, Voelkel NF, Yuan JX, Humbert M (2009) Inflammation, growth factors, and
pulmonary vascular remodeling. J Am Coll Cardiol 54:S10-S19
Hemnes AR, Zaiman A, Champion HC (2008) PDE5A inhibition attenuates bleomycin-induced
pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and
RhoA/Rho kinase activation. Am J Physiol Lung Cell Mol Physiol 294:L24-L33
Hentschel T, Yin N, Riad A, Habbazettl H, Weimann J, Koster A, Tschope C, Kuppe H,
Kuebler WM (2007) Inhalation of the phosphodiesterase-3 inhibitor milrinone attenuates
pulmonary hypertension in a rat model of congestive heart failure. Anesthesiology 106:
124-131
Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J (2004) Combination
therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir
J 24:1007-1010
Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, Duroux P,
Galanaud P, Simonneau G, Emilie D (1995) Increased interleukin-1 and interleukin-6 serum
concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 151:
1628-1631
Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW,
Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M (2004) Cellular and molecular
pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43:13S-24S
Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E,
Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M,
Hachulla E, Simonneau G (2006) Pulmonary arterial hypertension in France: results from a
national registry. Am J Respir Crit Care Med 173:1023-1030
Ichinose F, Adrie C, Hurford WE, Bloch KD, Zapol WM (1998) Selective pulmonary vasodilation
induced by aerosolized zaprinast. Anesthesiology 88:410-416
Izikki M, Raffestin B, Klar J, Hatzelmann A, Marx D, Tenor H, Zadigue P, Adnot S, Eddahibi S
(2009) Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-
induced pulmonary hypertension in rats. J Pharmacol Exp Ther 330:54-62
Jeffery TK, Wanstall JC (1998) Phosphodiesterase III and V inhibitors on pulmonary artery from
pulmonary hypertensive rats: differences between early and established pulmonary hyperten-
sion. J Cardiovasc Pharmacol 32:213-219
Jing ZC, Jiang X, Wu BX, Xu XQ, Wu Y, Ma CR, Wang Y, Yang YJ, Pu JL, Gao W (2009)
Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-
label study. Heart 95:1531-1536
Kemeny V, Molnar S, Andrejkovics M, Makai A, Csiba L (2005) Acute and chronic effects of
vinpocetine on cerebral hemodynamics and neuropsychological performance in multi-infarct
patients. J Clin Pharmacol 45:1048-1054
Keravis T, Thaseldar-Roumie R, Lugnier C (2005) Assessment of phosphodiesterase isozyme
contribution in cell and tissue extracts. Methods Mol Biol 307:63-74
Kim D, Rybalkin SD, Pi X, Wang Y, Zhang C, Munzel T, Beavo JA, Berk BC, Yan C (2001)
Upregulation of phosphodiesterase 1A1 expression is associated with the development of
nitrate tolerance. Circulation 104:2338-2343
Kim D, Aizawa T, Wei H, Pi X, Rybalkin SD, Berk BC, Yan C (2005) Angiotensin II increases
phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which
angiotensin II antagonizes cGMP signaling. J Mol Cell Cardiol 38:175-184
